The inhibition of the Fas–FasL interaction holds potential not only for novel and targeted treatment approaches for ischemic stroke injuries, but also for various central nervous system (CNS) diseases, including epilepsy, multiple sclerosis, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and stroke [27,33,34,35,36,37,38]. Here, FASLG is linked to ischemic stroke.